A vs CDXS
A: Agilent Technologies provides essential laboratory instruments, software, and services that power scientific discovery and clinical diagnostics. CDXS: Codexis uses its proprietary directed evolution technology to engineer enzymes that improve the manufacturing efficiency and sustainability of small molecule drugs and complex RNA therapeutics.
Side-by-side fundamentals
| Metric | A | CDXS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $168.17 | $1.36 | |
| Market cap | $47.4B | $149M | |
| P/E as of 2026-10-08 | 33.81 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 11.20 | n/a | |
| Net margin FY2025, SEC XBRL | +18.8% | -62.5% | A higher |
| Operating margin FY2025, SEC XBRL | +21.3% | -59.3% | A higher |
| ROE FY2025, SEC XBRL | +19.3% | -87.0% | A higher |
| ROA FY2025, SEC XBRL | +10.2% | -29.8% | A higher |
| Debt / equity as of 2026-09-03 | 0.47 | 1.24 | A lower |
| Revenue growth (YoY) as of 2026-09-03 | +9.1% | +35.9% | CDXS higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | -20.2% | A higher |
| Dividend yield as of 2026-09-03 | +0.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | A higher |
| Beta as of 2026-09-03 | 0.96 | 1.80 | |
| 1-year return as of 2026-10-08 close | +19.4% | -48.7% | A higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.